



FOR IMMEDIATE RELEASE

Contacts:

For Ohmx Corporation:

Erin Tower

Tel: (847) 491-4401

Fax: (847) 491-8510

erin@ohmx.com

Ohmx adds another paper to its growing publication list

Evanston IL, September 13th 2013 – Ohmx Corporation, a bioelectronic detection company focused on developing a Point-of-Care analyzer for monitoring of chronic diseases, is pleased to announce the publication of a scientific paper in *The Prostate*, published by John Wiley & Sons. This publication was first published online August 9th, 2013 and discusses a new biomarker suitable for assessing the aggressiveness of prostate cancer. It is the latest in a growing list of peer-reviewed publications and white papers available from the company.

PSA enzymatic activity: A new biomarker for assessing prostate cancer aggressiveness. M. J. Ahrens, P. A. Bertin, E. F. Vonesh, T. J. Meade, W. J. Catalona, D. G. Georganopoulou, *The Prostate* **2013**, DOI: **10. 1002/pros.22714**

Evolving Trends in Transition Metal-Modified Receptor Design and Function, P. A. Bertin Chapter contribution for the *Springer Series* on Chemical Sensors and Biosensors, **2012**, link.springer.com/bookseries/5346

Spectroscopic and Redox Properties of Amine-Functionalized $K_2[Os^{II}(bpy)(CN)_4]$ Complexes. M. J. Ahrens, P. A. Bertin, A. G. Gaustad, D. Georganopoulou, M. Wunder, G. F. Blackburn, H. B. Gray, & T. J. Meade. *Dalton Transactions* **2011**, 40, 1732, DOI: 10.1039/c0dt01478h

Ferrocene and maleimide-functionalized disulfide scaffolds for self-assembled Monolayers on gold. P. A. Bertin, M. J. Ahrens, K. Bhavsar, D. Georganopoulou, M. Wunder, G. F. Blackburn, T. J. Meade, *Organic Letters* **2010**, 12, 3372.

Novel redox active bifunctional crosslinkers from unsymmetrical 1,1'-disubstituted ferrocenes. P. A. Bertin, T. J. Meade, *Tetrahedron Letters* **2009**, 50, 5409.

Protein binding and the electronic properties of iron(II) complexes: An electrochemical and optical investigation of outer sphere effects. K. D. Barker, A. L. Eckermann, M. H. Sazinsky, M. R. Hartings, C. Abajian, D. Georganopoulou, M. A. Ratner, A. C. Rosenzweig, T. J. Meade, *Bioconjugate Chemistry* **2009**, 20, 1930.

Electroactive self-assembled monolayers on gold via bipodal dithiazepane anchoring groups. P. A. Bertin, D. Georganopoulou, T. Y. Liang, A. L. Eckermann, M. Wunder, M. J. Ahrens, G. F. Blackburn, T. J. Meade, *Langmuir* **2008**, 24, 9096.

About the Company:

Ohmx is a clinical diagnostic company that is developing a low-cost, bioelectronic, point-of-care (POC) reader that quantifies analytes from a low-volume biological sample (e.g. whole blood, urine, semen, prostatic fluid, etc). Ohmx's market entry strategy is based on a portable blood analyzer to assist clinicians with the diagnosis and monitoring of patients with chronic diseases in the physician office lab (POL) setting. The Ohmx POC device will enable doctors to quickly and cost-effectively diagnose, monitor and better manage patients with chronic diseases. The company's initial focus is on the diabetes market, with plans for cardiac markers and prostate cancer in the future.

This press release contains forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from the results identified or implied in any forward-looking statement. These statements are based on our views as of the date they are made with respect to future results or events. The Company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results or events expressed or implied therein will not be realized.